KLLN and renal cell carcinoma: Conclusively, circAMOTL1L may serve as an antioncogene in RCC progression, and a novel regulatory network involving the circAMOTL1L–miR-92a-2-5p–KLLN axis might serve as a therapeutic strategy for RCC.